# A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors

> **NCT06914128** · PHASE1,PHASE2 · RECRUITING · sponsor: **Bayer** · enrollment: 370 (estimated)

## Conditions studied

- MTAP-deleted Solid Tumors

## Interventions

- **DRUG:** BAY 3713372

## Key facts

- **NCT ID:** NCT06914128
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-21
- **Primary completion:** 2029-06-17
- **Final completion:** 2029-06-17
- **Target enrollment:** 370 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06914128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06914128, "A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06914128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*